Saturday 17 October 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
59.24
1.75
−2.87%
Follow PTCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 8.64 | 6.39 |
+8 more quarters Free account |
P/S ratio |
6.71 | 6.80 | 3.49 | 2.71 | |
P/FCF ratio |
0.00 | 0.00 | 13.62 | 10.79 | |
P/Operating CF |
52.44 | (95.22) | (176.27) | (72.63) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.39 | 7.67 | 3.87 | 3.10 | |
EV/EBITDA |
45.79 | 0.00 | 7.53 | 5.78 | |
EV/Operating CF |
(244.38) | (29.11) | 9.41 | 7.70 | |
EV/FCF |
(24.83) | (13.14) | 15.10 | 12.35 | |
Quick Ratio |
3.20 | 2.29 | 2.20 | 2.18 | |
Current Ratio |
3.39 | 2.44 | 2.35 | 2.32 | |
Net Debt/EBITDA |
4.27 | 12.55 | (10.33) | 83.37 | |
Debt/Assets |
89.60% | 91.11% | 89.62% | 90.10% | |
Debt/Equity |
(17.61) | (14.49) | (12.65) | (15.29) | |
Asset Turnover |
0.34 | 0.30 | 0.75 | 0.79 | |
Operating CF/Net income |
1.55 | 21.02 | 0.25 | (4.17) | |
Capex/Depreciation |
(0.64) | (0.11) | (0.29) | (48.24) | |
Interest Coverage |
3.07 | 0.92 | (1.29) | 0.09 | |
Research and Development Expense of Revenue |
27.50% | 37.01% | 80.84% | 47.47% | |
Selling, General and Administrative Expense of Revenue |
22.36% | 31.62% | 58.83% | 39.83% | |
Intangible Assets out of Total Assets |
0.15 | 0.16 | 0.16 | 0.18 | |
Share Based Compensation of Revenue |
6.46% | 8.59% | 11.25% | 9.21% | |
Graham Net Nets |
(0.12) | (0.14) | (0.14) | (0.16) | |
Graham Number |
4.69 | 10.71 | 0.00 | 0.00 | |
Earnings Yield |
(0.60%) | (3.42%) | 11.57% | 15.66% | |
Free Cash Flow Yield |
(4.43%) | (8.59%) | 7.34% | 9.27% | |
Revenue per Share |
4.34 | 3.30 | 2.07 | 2.69 | |
Operating CF per Share |
1.56 | (0.72) | (0.43) | (0.84) | |
Capex per Share |
(0.09) | (0.02) | (0.03) | (3.26) | |
Free Cash Flow per Share |
1.47 | (0.73) | (0.46) | (4.11) | |
Cash per Share |
26.85 | 22.93 | 24.46 | 21.51 | |
Shareholders Equity per Share |
(1.99) | (2.19) | (2.58) | (1.98) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.99) | (2.19) | (2.58) | (1.98) | |
Free Cash Flow |
121.97 | (60.39) | (36.65) | (322.50) | |
Working Capital |
1,846.29 | 1,330.40 | 1,305.52 | 1,141.56 | |
Capital Expenditures |
(7.14) | (1.35) | (2.37) | (256.19) | |
Net Current Asset Value |
(798.48) | (795.57) | (830.13) | (791.65) | |
EV/EBIT |
59.35 | 0.00 | 7.72 | 7.10 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 1.21 | |
Price to Operating Income |
53.91 | 0.00 | 6.97 | 6.21 | |
| Other line items | |||||
Average Receivables |
217.59 | 215.21 | 170.09 | 201.53 | |
Average Payables |
360.60 | 315.43 | 342.78 | 319.74 | |
Average Inventory |
62.71 | 48.62 | 51.42 | 44.18 | |
Average Assets |
2,942.32 | 2,762.25 | 2,301.90 | 2,242.97 | |
Average Common Equity |
(185.95) | (183.11) | (651.69) | (605.05) |
Columns are period end dates